Halozyme issues position statement on CMS final IPAY 2028 Medicare negotiation guidance

HALOZYME THERAPEUTICS, INC.

Statement includes long-term projections of U.S. Medicare Part B spend as % of total ENHANZE partner product SC sales.
No specific financial projections or quantitative details were disclosed in the 8-K or attached exhibit.
The exhibit text provided is only a title; substantive content must be accessed on the company's website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.